Welcome to the CJU website »
LOG IN
Indexed in Index Medicus and Medline
HOW I DO IT
-
The Rezūm system - a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia
Cantrill H. Christopher, Zorn C. Kevin, Elterman S. Dean, Gonzalez R. Ricardo, MD Urology San Antonio, San Antonio, Texas, USA
Benign prostatic hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) sits in the top ten prominent and costly disease conditions in men over 50 years of age. In the United States it is the most common diagnosis made by urologists for men 45 to 74 years of age. Twenty percent of the population will reach 65 years of age or older by 2030, and those over 85 years will represent the fastest growing segment of our population. The prevalence of symptomatic BPH increases proportionally with the aging population. It is estimated that BPH now affects 6% of the male population worldwide. Moreover, in Canada, the estimated BPH prevalence is more than 1 million men aged 50 years and older. Among the various surgical treatments, Rezūm water vapor thermal therapy has been developed as a unique, rapid and reproducible minimally invasive surgical treatment exhibiting safe and early effective relief of LUTS/BPH. The targeted prostate tissue ablation is amenable to all zones of the prostate including intravesical median lobes. We present our experiences with this technique, which can be quickly performed under local anesthesia in an office setting.
Keywords: benign prostatic hyperplasia, prostate, LUTS, water vapor thermal therapy, Rezum system, minimally invasive surgical treatment,
Jun 2019 (Vol. 26, Issue 3 , Page 9787) -
How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer
Moul W. Judd, MD Division of Urology, Department of Surgery and Duke Cancer Institute, Durham, North Carolina, USA
Urologists have been using oral nonsteroidal antiandrogens (AA) for 30 years as a component of combined androgen blockade. In February 2018, a new third generation AA, apalutamide, became available for the first time for non-metastatic (M0) castrate resistant prostate cancer (CRPC). Apalutamide was found to delay the presence of metastases (metastases free survival-MFS) by approximately 2 years versus placebo in M0 CRPC. While overall survival benefit has yet to be established, the MFS benefit is clinically meaningful and urology practices should be equipped to manage patients using this new oral agent. Since the majority of patients remain under urologic care when this disease stage develops and because the drug is straightforward to administer, urology practices are ideal to identify and treat. The objective of this brief article is to discuss the typical patient profile for use of apalutamide and to review the pros and cons of use and common side effects and management.
Keywords: prostate cancer, apalutamide, castrate-resistant, non-metastatic disease, antiandrogen,
Jun 2019 (Vol. 26, Issue 3 , Page 9782) -
How I do it: Surgically inserted transversus abdominis plane (TAP) catheters for flank incisions
Khurana Jaasmit, Ip Vivian, Todd Gerald, Sondekoppam V. Rakesh, MD Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, Alberta, Canada
Pain control following major abdominal surgery remains a significant barrier to patient comfort. Although thoracic epidurals have been used to provide analgesia for these surgeries, the transversus abdominis plane (TAP) block is gaining popularity. The TAP catheter insertion method has transformed over the past two decades from a blinded technique to one conducted primarily under ultrasound guidance by anesthesiologists. Recently, however, interest has increased on the potential for direct surgical insertion of catheters into the TAP plane following flank incisions due to anatomical considerations. Proposed advantages include a reduction in operating time, requirement of minimal expertise and increased accuracy of catheter placement. In this report, we describe the rationale and the technique of surgical insertion of TAP catheters following open nephrectomies as performed by urologists at our institution.
Keywords: transversus abdominis plane block, nerve block, open nephrectomy,
Dec 2018 (Vol. 25, Issue 6 , Page 9623)PDF (655.9KB)Free -
How I Do It: Hydrogel spacer placement in men scheduled to undergo prostate radiotherapy
Montoya Juan, Gross Eric, Karsh Lawrence, MD The Urology Center of Colorado, Denver, Colorado, USA
Hydrogel spacer placement between the prostate and rectum in men scheduled to undergo prostate radiotherapy is an emerging technique well suited for urologists. The hydrogel spacer reduces rectal injury during radiotherapy by displacing the rectum away from the high dose region. Following radiotherapy the hydrogel spacer then liquifies, is absorbed, and then clears via renal filtration in approximately 6 months. Herein we describe the appropriate patients eligible for this procedure, and the application technique we use in our clinic.
Keywords: prostate cancer, radiotherapy, hydrogel spacer, application, quality of life,
Apr 2018 (Vol. 25, Issue 2 , Page 9288) -
How I do it: Balloon tamponade of prostatic fossa following Aquablation
Aljuri Nikolai, Gilling Peter, Roehrborn Claus, MD PROCEPT BioRobotics Corporation, Redwood Shores, California, USA
Since its first report in the 1870s, control of bleeding after transurethral resection of the prostate (TURP) has remained a concern. Foley's initial report of a urinary catheter involved placement of the balloon into the prostatic fossa following TURP. Removal of prostate tissue with a high-velocity saline stream (Aquablation) is a recently reported alternative to TURP. As Aquablation is heat-free, alternatives to non-thermal hemostasis were sought to optimize the procedure. We report use of a balloon catheter in the prostatic fossa after Aquablation as a post-resection hemostatic method.
Keywords: benign prostatic hyperplasia, aquablation, bladder outlet obstruction, minimally invasive robotic surgery, balloon catheter, TURP,
Aug 2017 (Vol. 24, Issue 4 , Page 8937)
